Vatican Endorsement Seals Neostem's Status as Leading Stem Cell Play
M.E. Garza submits: Just as we have speculated in articles and trade alerts for the past few weeks, the Roman Catholic church appears to be getting ready to support Neostem's (AMEX:NBS) stem cell initiatives in a very big way and one can only imagine the types of new headlines this news may generate both on and off Wall Street. One of the biggest questions now is just how high NBS shares will run on news of the scientific support that would have made Galileo jealous. An easy double? Perhaps easily over $10 or $15, given the fact that the company should be easily trading at $6 per share now without the news? Analysts I spoke to Wednesday morning say it's too soon to tell since historic news like this isn't announced very often.NBS announced Wednesday morning that the Vatican’s Pontifical Council for Culture announced a joint 5 year initiative between the companies and their charitable organizations to expand research and raise awareness of adult stem cell therapies. NeoStem’s Stem for Life Foundation, formed to create awareness about the promise of adult stem cells to treat disease, and the Pontifical Council’s Foundation, called STOQ International (Science Theology and the Ontological Quest), will work on a variety of collaborative activities with the goal of advancing scientific research on adult stem cells, exploring their clinical application in the field of regenerative medicine and the cultural relevance of such a fundamental shift in medical treatment options, particularly with regard to the impact on theological and ethical issues. As we understand it, this Vatican has endorsed NBS's method of extraction and storage of autologus (self-derived) adult stem cells as well as the growing number of NBS's proprietary treatments for these cells in the orthopedic, cardiovascular, and cosmetic areas.Complete Story » seekingalpha.com |
Trading Binary Bio Events: Amarin, ChemGenex, AstraZeneca
Mike Havrilla submits:Beyond the Bio Run-Up strategy of selecting a basket of small/micro-cap stocks with pending binary events such as FDA decisions and clinical trial results, another means of achieving diversification is by selecting a basket of companies with different types of pending catalysts. Below are some examples of how to categorize pending bio-catalyst events and some specific examples for each category. 1.) Long-Term Hold: Amarin Corp. (NASDAQ:AMRN) ($2.37, $234 million market cap)Complete Story » seekingalpha.com |
Merck: All Kids' Vaccines Now Available
Merck said that for the first time since 2007, its entire lineup of pediatric vaccines is now available—a milestone in the company's efforts to recover from a series of vaccine manufacturing and supply setbacks. online.wsj.com |
Who are you calling obese? - Video
Anytime Fitness Launches Provocative Campaign, Challenging Parents to Lead the Way feedproxy.google.com |
Ryan & Maniskas, LLP Announces Investigation of Clarient, Inc.
[Business Wire] - Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Clarient, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s efforts to sell Clarient to GE Healthcare, a unit of General Electric Company in a transaction with a value of approximately $580 million. us.rd.yahoo.com |